• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

纳米结晶制剂产业化研究进展

曾泷彪, 廉云飞, 张军东, 唐文燕, 李娟

曾泷彪, 廉云飞, 张军东, 唐文燕, 李娟. 纳米结晶制剂产业化研究进展[J]. 中国药科大学学报, 2013, 44(6): 504-510. DOI: 10.11665/j.issn.1000-5048.20130603
引用本文: 曾泷彪, 廉云飞, 张军东, 唐文燕, 李娟. 纳米结晶制剂产业化研究进展[J]. 中国药科大学学报, 2013, 44(6): 504-510. DOI: 10.11665/j.issn.1000-5048.20130603
shu
ZENG Longbiao, LIAN Yunfei, ZHANG Jundong, TANG Wenyan, LI Juan. Progress in the industrialization of nanocrystal technology[J]. Journal of China Pharmaceutical University, 2013, 44(6): 504-510. DOI: 10.11665/j.issn.1000-5048.20130603
Citation: ZENG Longbiao, LIAN Yunfei, ZHANG Jundong, TANG Wenyan, LI Juan. Progress in the industrialization of nanocrystal technology[J]. Journal of China Pharmaceutical University, 2013, 44(6): 504-510. DOI: 10.11665/j.issn.1000-5048.20130603
shu

纳米结晶制剂产业化研究进展

  • 1.

    中国药科大学药剂学教研室

  • 2.

    上海信谊药厂有限公司药物研究所

基金项目: 上海市科技支撑计划资助项目(No.10dz1920400)

Progress in the industrialization of nanocrystal technology

摘要

    摘要
  • 摘要: 随着10种纳米结晶制剂先后上市，纳米结晶技术逐渐发展成为一种成熟的技术工艺，该技术能提高药物的饱和溶解度、改善药物的溶出速率从而提高其在体内的生物利用度。随着新设备、新材料的出现，纳米结晶制剂技术也逐步呈现可控化和产业化，不同给药方式的纳米结晶制剂先后上市或进入临床研究阶段。本文综述了纳米结晶制剂的产业化生产技术、生产过程中关键工艺参数、稳定剂对产品的影响，以及利用纳米结晶技术上市或进入临床研究的药物等。
    Abstract: In the past decade, more maturing nanocrystal technology brought about commercial marketing of ten kinds of nanocrystal formulation. The saturated solubility, dissolution rate and oral bioavailability could be improved. Emergence of new equipments and materials ensured the controllability and industrialization in the adaptation of nanocrystal technology. Nanocrystal formulations for the different routes of administration are available or in clinical investigation. This paper summarized the industrial production methods, the key processing parameters, the effects of stability-enhancer on the nanocrystal formulations, and the drugs on the market or in clinical study.
    • HTML全文
    • 参考文献(36)
  • [1] Pardeike J,Müller RH.Nanosuspensions:a promising formulation for the new phospholipase A2 inhibitor PX-18[J].Int J Pharm,2010,391(1/2):322-329.
    [2] Shegokar R,Müller RH.Nanocrystals:industrially feasible multifunctional formulation technology for poorly soluble actives[J].Int J Pharm,2010,399(1/2):129-139.
    [3] Rabinow BE. Nanosuspensions in drug delivery[J]. Nat Rev Drug Discov,2004,3(9):785-796.
    [4] Chaubal MV,Popescu C.Conversion of nanosuspensions into dry powders by spray drying:a case study[J].Pharm Res,2008,25(10):2 302-2 308.
    [5] Beirowski J, Inghelbrecht S, Arien A, et al. Freeze-drying of nanosuspensions,1:freezing rate versus formulation design as critical factors to preserve the original particle size distribution[J].Int J Pharm,2011,100(5):1 958-1 968.
    [6] Bose S,Sshenck D,Ghosh I,et al.Application of spray granulation for conversion of a nanosuspension into a dry powder form[J].Eur J Pharm Sci,2012,47(1):35-43.
    [7] Müller RH,Gohla S,Keck CM.State of the art of nanocrystals-Special features,production,nanotoxicology aspects and intracellular delivery[J].Eur J Pharm Biopharm 2011,78(1):1-9.
    [8] Verma S,Gokhale R,Burgess DJ.A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions[J].Int J Pharm,2009,380(12):216-222.
    [9] Gao L,Zhang DR,Chen MH.Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system[J].J Nanopart Res,2008,10(5):845-862.
    [10] Peltonen L,Hirvonen J.Pharmaceutical nanocrystals by nanomilling:critical process parameters,particle fracturing and stabilization methods[J].J Pharm Pharmacol,2010,62(11):1 569-1 579.
    [11] Kakran M,Shegokar R,Sahoo NG,et al.Fabrication of quercetin nanocrystals:comparison of different methods[J].Eur J Pharm Biopharm,2012,80(1):113-121.
    [12] Singare DS,Marella S,Gowthamrajan K,et al.Optimization of formulation and process variable of nanosuspension:an industrial perspective[J].Int J Pharm,2010,402(1/2):213-220.
    [13] Salazar J,Heinzerling O,Müller RH,et al.Process optimization of a novel production method for nanosuspensions using design of experiments(DoE)[J].Int J Pharm,2011,420(2):395-403.
    [14] Keck CM,Müller RH.Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation[J].Eur J Pharm Biopharm,2006,62(1):3-16.
    [15] Salazar J,Ghanem A,Müller RH,et al.Nanocrystals:comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches[J].Eur J Pharm Biopharm,2012,81(1):82-90.
    [16] Eerdenbrugh BV,Mooter GV,Augustijns P.Top-down production of drug nanocrystals:nanosuspension stabilization,miniaturization and transformation into solid products[J].Int J Pharm,2008,364(1):64-75.
    [17] Wu LB,Zhang J,Watanabe W.Physical and chemical stability of drug nanoparticles[J].Adv Drug Deliv Rev,2011,63(6):456-469.
    [18] Xia DN,Quan P,Piao HZ,et al.Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability[J].Eur J Pharm Sci,2010,40(4):325-334.
    [19] Merisko-Liversidge E, Liversidge G. Nanosizing for oral and parenteral drug delivery:a perspective on formulating poorly-water soluble compounds using wet media milling technology[J].Adv Drug Deliv Rev,2011,63(6):427-440.
    [20] Zhang X,Sun N,Wu B,et al.Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique[J].Powder Technol,2008,182(3):480-485.
    [21] Mishra PR,Shaal LA,Müller RH,et al.Production and characte-rization of hesperetin nanosuspensions for dermal delivery[J].Int J Pharm,2009,371(1/2):182-189.
    [22] Li W,Yang YG,Tian YS,et al.Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension[J].Int J Pharm,2011,408(1/2):157-162.
    [23] Pardeike J,Strohmeier DM,Schrodl N,et al.Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines[J].Int J Pharm,2011,420(1):93-100.
    [24] Xu Y,Lu Y,Qi JP,et al.Preparation and characterization of simvastatin nanocrystal[J].China Science Paper(中国科技论文),2012,7(3):219-223.
    [25] Kassem MA,Abdel Rahman AA,Ghorab MM,et al.Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs[J].Int J Pharm,2007,340(1/2):126-133.
    [26] Shaal LA,Shegokar R,Müller RH.Production and characterization of antioxidant apigenin nanocrystals as a novel UV skin protective formulation[J].Int J Pharm,2011,420(1):133-140.
    [27] Li XM,Gu L,Wang YL,et al.Preparation of fenofibrate nunosuspension by melt-emulsification[J].Chin J Pharm(中国医药工业杂志),2009,40(5):349-354.
    [28] Fakes MG,Vakkalagadda BJ,Qian F,et al.Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches[J].Int J Pharm,2009,370(1/2):167-174.
    [29] Gao L,Zhang DR,Chen MH,et al.Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions[J].Int J Pharm,2008,355(1/2):321-327.
    [30] Ali HSM,York P,Blagden N.Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors[J].Int J Pharm,2009,375(1/2):107-113.
    [31] Xiong RL,Lu WG,Li J,et al.Preparation and characterization of intravenously injectable nimodipine nanosuspension[J].Int J Pharm,2008,350(1/2):338-343.
    [32] Zheng DD,Wang YC,Zhang DR,et al.In vitro antitumor activity of silybin nanosuspension in PC-3 cells[J].Cancer Lett,2011,307(2):158-164.
    [33] Teeranachaideekul V,Junyaprasert VB,Souto EB,et al.Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology[J].Int J Pharm,2008,354(1/2):227-234.
    [34] Wu Y,Loper A,Landis E,et al.The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869:a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human[J].Int J Pharm,2004,285(1/2):135-146.
    [35] Pu XH,Sun J,Li M,et al.Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs[J].Curr Nanosci,2009,5(4):417-427.
    [36] Müller RH,Keck CM.Twenty years of drug nanocrystals:where are we,and where do we go[J]?Eur J Pharm Biopharm,2012,80(1):1-3.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 刊出日期:  2013-12-24

目录

摘要
HTML全文
    参考文献(36)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：336042

    x 关闭 永久关闭